Cell associate RNA (caRNA) was extracted with the RNeasy kit (Qiagen) following manufacturers protocol. Violet. (C) Cells were further gated on CD3+/GFP+ (infected cells) or CD4+/GFP? (uninfected cells). Further gating based of GFP expression allowed separation into high JNJ-10397049 and low GFP expressing cells. Relative viability of uninfected control cells (CD3+/CD4+/GFP?) in each well was assessed in parallel. (D) Gating on effector cells was made by a live CD3+/CD8+ gate. (E) For B cell killing, the gating was made on CD3?/CD19+ live cells. NIHMS1544021-product-2.pdf (853K) GUID:?60CF9F30-9D4B-4E98-AE09-E0C6304FAFD4 3: Physique JNJ-10397049 S3: Specific killing of HIV-infected main spleen CD4 T-cells by cCAR-T cells combined with HIV Env-specific MicAbodies. Related to Physique 2.Specific killing of R5 tropic HIV-1 (BaL)-infected spleen cells by cCAR-T cells armed with 4 different HIV Env-specific MicAbodies. One million splenocytes made up of approximately 1104 infected CD4 T-cells were incubated with 1105 CAR-T cells for 48 hours, in the presence of different concentrations (10C500 pM) of HIV Env-specific MicAbodies. B-cell-specific MicAbody (Ritux) and anti-HER2 MicAbody (HER2) were incorporated as unfavorable controls. Results are presented relative to the No cCAR-T cell control. For each individual MicAbody, an internal control of no cCAR-T cell supplemented with the highest MicAbody concentration tested is presented. Results are cumulated from four impartial experiments. Data are represented as mean + SEM. * = p0.05, ** = p0.01, *** = p0.001, compared to no MicAbody. NIHMS1544021-product-3.pdf (162K) GUID:?46D90A2F-9374-4573-8B29-5DE60F41D8B3 4: Figure S4: Comparison of cCAR-T killing of HIV-infected cells present in activated PBMC versus tonsil derived cells. Related to Physique 6.F4-HIV-infected cells from tonsil (HLAC) or activated blood cells (PBMC) were cultured with cCAR-T cells at a 10:1 effector-to-target ratio for 48 hours JNJ-10397049 in the presence of a mix of four HIV MicAbodies, or HER-2 MicAbody. GFP+ cell number was measured by circulation cytometry and data are offered relative to cCAR-T with no MicAbody present. NIHMS1544021-product-4.pdf (438K) GUID:?00FA9870-07FE-4817-8B6D-2BC5109837B8 5: Figure S5: Specific killing of CXCR4 tropic HIV-infected main CD4 T cells by cCAR-T cells combined with specific HIV MicAbodies. Related to Physique 2.Specific killing of X4-tropic HIV-1 (NL4C3) infected tonsil (A), spleen (B), or blood cells (C) by 4 single HIV-specific MicAbodies with cCAR-T cells was assessed. One million main cells (~1104 infected cells) were incubated with 1105 CAR-T cells for 48 hours Rabbit Polyclonal to NMBR in the presence of different concentrations (10C500 pM) of the HIV Env-specific MicAbodies. B cell-specific MicAbody (Ritux) and anti-HER2 MicAbody (HER2) were used as unfavorable MicAbody controls. Results are presented for each individual MicAbody, no cCAR-T cells and donor-matched untransduced CD8 cells supplemented with the highest MicAbody concentration tested are included as controls. Results are cumulated from three impartial experiments for each tissue. Data are represented as mean + SEM relative to the CD8 control. * = p0.05, ** = p0.01 NIHMS1544021-product-5.pdf (526K) GUID:?025B8ECF-276C-4340-B00B-3F7927FF8B5D 6: Movie S1: Time lapse microscopy of cCAR-T cell killing assay. Related to physique 4. NIHMS1544021-product-6.avi (5.6M) GUID:?A4596383-DFF9-4B5F-B657-0675BCE46296 7. NIHMS1544021-product-7.pdf (58K) GUID:?1EED1899-1C16-4360-BCD2-EFE75716F7B9 Data Availability StatementThis study did not generate datasets. Summary Current approaches to reducing the latent HIV reservoir entail first reactivating virus-containing cells JNJ-10397049 to become visible to the immune system. A critical second step is usually killing these cells to reduce reservoir size. Endogenous cytotoxic T-lymphocytes (CTLs) may not be adequate because of cellular exhaustion and the development of CTL-resistant viruses. We have designed a universal CAR-T cell platform based on CTLs designed to bind a variety of broadly neutralizing anti-HIV antibodies. We show that this platform, killing by JNJ-10397049 the cCAR-T platform. Comparison of the.